I-MAB SPONS.ADS/1 -0001 (0VY) - Total Assets
Based on the latest financial reports, I-MAB SPONS.ADS/1 -0001 (0VY) holds total assets worth €260.52 Million EUR (≈ $304.58 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
I-MAB SPONS.ADS/1 -0001 - Total Assets Trend (2021–2025)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's total assets have evolved over time, based on quarterly financial data. Also see 0VY stock market capitalisation for the company's overall valuation and market capitalisation.
I-MAB SPONS.ADS/1 -0001 - Asset Composition Analysis
Current Asset Composition (December 2025)
I-MAB SPONS.ADS/1 -0001's total assets of €260.52 Million consist of 83.5% current assets and 16.5% non-current assets. Review 0VY total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 80.9% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See I-MAB SPONS.ADS/1 -0001 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: I-MAB SPONS.ADS/1 -0001's current assets represent 83.5% of total assets in 2025, a decrease from 85.4% in 2021.
- Cash Position: Cash and equivalents constituted 80.9% of total assets in 2025, up from 62.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
I-MAB SPONS.ADS/1 -0001 Competitors by Total Assets
Key competitors of I-MAB SPONS.ADS/1 -0001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
I-MAB SPONS.ADS/1 -0001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.09 | 20.90 | 15.99 |
| Quick Ratio | 8.09 | 20.90 | 15.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €190.63 Million | €168.24 Million | €176.44 Million |
I-MAB SPONS.ADS/1 -0001 - Advanced Valuation Insights
This section examines the relationship between I-MAB SPONS.ADS/1 -0001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.09 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | 22.5% |
| Total Assets | €260.52 Million |
| Market Capitalization | $189.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values I-MAB SPONS.ADS/1 -0001's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: I-MAB SPONS.ADS/1 -0001's assets grew by 22.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for I-MAB SPONS.ADS/1 -0001 (2021–2025)
The table below shows the annual total assets of I-MAB SPONS.ADS/1 -0001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €260.52 Million ≈ $304.58 Million |
+22.49% |
| 2024-12-31 | €212.68 Million ≈ $248.65 Million |
-42.35% |
| 2023-12-31 | €368.92 Million ≈ $431.31 Million |
-37.52% |
| 2022-12-31 | €590.45 Million ≈ $690.29 Million |
-32.81% |
| 2021-12-31 | €878.74 Million ≈ $1.03 Billion |
-- |
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more